Form 4: Arcturus Therapeutics Director Peter Farrell Reports Stock Transactions
SEC Form 4 Filing
Director Peter Farrell reports acquisition and disposal of Arcturus Therapeutics stock and derivative securities.
Summary
- Peter Farrell, a director of Arcturus Therapeutics Holdings Inc., reported transactions involving the company's stock on June 14, 2024.
- Farrell acquired 3,131 shares of common stock through the vesting of deferred stock units.
- These deferred stock units were part of the 2023 annual grant and vested at the company's 2024 annual meeting.
- Farrell also acquired 15,000 shares underlying a stock option with an exercise price of $31, vesting monthly over one year from the grant date.
- Following these transactions, Farrell directly owns 55,741 shares of common stock and indirectly owns 42,955 shares through the Peter C. Farrell Trust.
- He also holds options for 15,000 shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedule of the stock options (monthly over one year) suggests a continued involvement and interest from the director.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge sentiment and potential future actions of key personnel.
Comparison to Industry Standards
- Stock option grants to board members are a common practice in the biotechnology industry to align their interests with those of shareholders.
- The vesting schedule of the options (monthly over one year) is fairly standard.
- The size of the grant (15,000 shares) would need to be compared to grants at peer companies to determine if it is above or below average.
Stakeholder Impact
- Shareholders may be interested in the transactions of company insiders as an indicator of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| August 1, 2023 | Date of grant for the deferred stock units as part of the 2023 annual grant. |
| June 14, 2024 | Date of the transactions: vesting of deferred stock units and grant of stock options; also the date of the Issuer's 2024 annual meeting of stockholders. |
| June 14, 2034 | Expiration date of the stock options. |
| June 18, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.